about
Gemcitabine eliminates double minute chromosomes from human ovarian cancer cellsWithaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cellsGemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)Targeting SRC in mucinous ovarian carcinoma.Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancerWithaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancerThe small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells.Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.Therapeutic strategies in epithelial ovarian cancer.Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines.Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.Overcoming platinum resistance through the use of a copper-lowering agentComplete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature.Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer.DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancerXenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination SystemPlatelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.2-Deoxy-d-Glucose Sensitizes Human Ovarian Cancer Cells to Cisplatin by Increasing ER Stress and Decreasing ATP Stores in Acidic Vesicles.BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.Myriocin induces apoptotic lung cancer cell death via activation of DR4 pathway.Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer.Long-term pegylated liposomal doxorubicin use and oromaxillary squamous cell carcinoma in endometrial cancer.Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells.Verrucarin J inhibits ovarian cancer and targets cancer stem cells.Repositioning of proton pump inhibitors in cancer therapy.Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).Successful resuscitation after cardiac arrest secondary to carboplatin infusion: A case report.Nivolumab use for gene mutation carriers with recurrent epithelial ovarian cancer: A case seriesMonepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies
P2860
Q28535582-A75D1D30-2CFE-4D3C-A3FC-9B77F0923300Q28543359-CAD65E6A-5B1F-40D8-B5F5-635BF9BBE5C2Q33578254-DC3056AD-FDAE-4566-B364-C7D8025D9DBDQ33638051-7DAD72A7-DB41-4548-9A44-F28122F46158Q34219967-7D856B6B-5C6A-43E4-8DC1-9B1C8DD7336FQ34241202-4545F80D-C3EF-41DE-8A33-248B9CAC97B1Q34292101-1BE08DE9-929F-4107-87C8-4718E785D553Q34347621-403CF55E-3245-47E8-A83C-2FF7976C4437Q35109273-C21520D0-34B7-44BF-9173-D0C17E48A8C4Q35653739-4462A529-612E-4ED9-90B6-7B13D43C68E0Q35845484-EEEC80E7-4703-474C-B0D9-40643DFCFF94Q36109004-F02504D6-B258-4C08-A638-6B8539A457C8Q36249363-BCF3DA57-F93C-4934-B9D0-C08B6F2E1F24Q36544294-80B5EDC8-8F69-431A-87F2-812DFACDCC5BQ36545468-DC3DE8A3-4669-455C-A6AC-BE8481FDBE94Q36886892-3C1DE5C6-FD05-4A8C-A65D-94B84968342BQ36918550-83ED55B4-0456-46A8-9F17-DC88915F44F4Q37046805-74BB9080-9AFE-40F1-8625-8FD591A0ECF4Q37113732-9B413131-7B00-4C6B-97CC-E31CFA317B52Q37225627-19182EA4-5875-4435-AE4C-4D9CD5714832Q37276254-A83E614E-7387-445F-AD26-50CB1733D196Q37295618-057C57D5-C420-4F74-BFB3-1BD01214A9EBQ37530604-803EBE81-85E5-41A9-8764-BF1B1D690F4CQ37611723-DEF83184-8700-4852-A320-65FF62D28D98Q37625369-3D22764E-02CC-4719-8683-6A45A3ECF379Q38813996-10438241-3F0A-4C2E-8471-C668D767344DQ38846410-D4F0289B-CAD4-4A00-AF9B-6DDABF28F86EQ38965047-A1BF494E-1031-4408-B6A2-74AD7464801DQ38966925-243B4EC9-BB69-4C86-ADB0-C97E16F5332CQ39036953-044E8E3D-93EB-4554-B7FB-CEEA5E36C3BFQ40571932-4D3C3F9F-C3B8-4490-B6EB-4B278EC3DE78Q42425714-3B1887F8-1071-4818-B401-F768E384AEA9Q42708068-6F12808E-F9A2-46F4-A93A-9F3C38550522Q46070440-A3A6828B-E6E3-42F0-8780-43653E703302Q46250945-EE15867E-17EE-41D3-BC98-B1DF48E6A26CQ48142620-150BF15F-36FE-48A3-AF48-2B886826C569Q48617362-9665C689-28CB-4871-B482-AAB8A293B897Q55436471-91D94E25-E425-4CE4-954B-C48B4F34E7B5Q57210400-3B3458E4-E264-443E-8673-0F7A58E72820Q58790039-31BECAAF-25E3-4B8C-88BF-6EA33FA585E0
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Overcoming platinum resistance in ovarian carcinoma.
@ast
Overcoming platinum resistance in ovarian carcinoma.
@en
Overcoming platinum resistance in ovarian carcinoma.
@nl
type
label
Overcoming platinum resistance in ovarian carcinoma.
@ast
Overcoming platinum resistance in ovarian carcinoma.
@en
Overcoming platinum resistance in ovarian carcinoma.
@nl
prefLabel
Overcoming platinum resistance in ovarian carcinoma.
@ast
Overcoming platinum resistance in ovarian carcinoma.
@en
Overcoming platinum resistance in ovarian carcinoma.
@nl
P2093
P2860
P1476
Overcoming platinum resistance in ovarian carcinoma.
@en
P2093
Anil K Sood
Koji Matsuo
Lynda D Roman
Yvonne G Lin
P2860
P304
P356
10.1517/13543784.2010.515585
P407
P577
2010-09-06T00:00:00Z